JP7684788B2 - 代謝疾患を治療する組成物と方法 - Google Patents

代謝疾患を治療する組成物と方法 Download PDF

Info

Publication number
JP7684788B2
JP7684788B2 JP2018562995A JP2018562995A JP7684788B2 JP 7684788 B2 JP7684788 B2 JP 7684788B2 JP 2018562995 A JP2018562995 A JP 2018562995A JP 2018562995 A JP2018562995 A JP 2018562995A JP 7684788 B2 JP7684788 B2 JP 7684788B2
Authority
JP
Japan
Prior art keywords
polypeptide
cmyr
serum
polypeptides
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520341A (ja
JP2019520341A5 (enExample
Inventor
リウ，ホンリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI HEP PHARMACEUTICAL Co Ltd
Original Assignee
SHANGHAI HEP PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI HEP PHARMACEUTICAL Co Ltd filed Critical SHANGHAI HEP PHARMACEUTICAL Co Ltd
Publication of JP2019520341A publication Critical patent/JP2019520341A/ja
Publication of JP2019520341A5 publication Critical patent/JP2019520341A5/ja
Application granted granted Critical
Publication of JP7684788B2 publication Critical patent/JP7684788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2018562995A 2016-05-30 2017-05-31 代謝疾患を治療する組成物と方法 Active JP7684788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610370442.4 2016-05-30
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (3)

Publication Number Publication Date
JP2019520341A JP2019520341A (ja) 2019-07-18
JP2019520341A5 JP2019520341A5 (enExample) 2020-07-02
JP7684788B2 true JP7684788B2 (ja) 2025-05-28

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562995A Active JP7684788B2 (ja) 2016-05-30 2017-05-31 代謝疾患を治療する組成物と方法

Country Status (10)

Country Link
US (2) US11633454B2 (enExample)
EP (1) EP3463422B1 (enExample)
JP (1) JP7684788B2 (enExample)
KR (1) KR102627084B1 (enExample)
CN (1) CN109310737B (enExample)
AU (1) AU2017274094B2 (enExample)
CA (1) CA3026140A1 (enExample)
DK (1) DK3463422T3 (enExample)
ES (1) ES2979305T3 (enExample)
WO (1) WO2017206898A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240058393A1 (en) * 2020-12-28 2024-02-22 Md Healthcare Inc. Composition comprising micrococcus luteus-derived extracellular vesicle for prevention or treatment of metabolic disease
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130316B (zh) 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
DK2917231T3 (da) * 2012-11-12 2019-06-11 Univ Heidelberg Ruprecht Karls Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3204030B1 (en) 2014-10-07 2022-04-27 Myr GmbH Combination therapy of hbv and hdv infection
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
EP3189850A1 (en) 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hepatology (2014) vol.60, no.5, p.1458-1460
Hepatology (2014) vol.60, no.5, p.1483-1493
XXIII INTERNATIONAL BILE ACID MEETING BILE ACIDS AS SIGNAL INTEGRATORS AND METABOLIC MODULATORS; OCT, 2014, FREIBERG GERMANY(201) VOL.194, P.102

Also Published As

Publication number Publication date
CN109310737A (zh) 2019-02-05
EP3463422A1 (en) 2019-04-10
AU2017274094A1 (en) 2019-02-14
US11633454B2 (en) 2023-04-25
ES2979305T3 (es) 2024-09-25
JP2019520341A (ja) 2019-07-18
CA3026140A1 (en) 2017-12-07
EP3463422A4 (en) 2020-02-26
DK3463422T3 (da) 2024-07-22
KR20190015392A (ko) 2019-02-13
US20230414706A1 (en) 2023-12-28
CN109310737B (zh) 2023-05-05
US20200323951A1 (en) 2020-10-15
EP3463422B1 (en) 2024-05-22
AU2017274094B2 (en) 2020-09-10
KR102627084B1 (ko) 2024-01-19
WO2017206898A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
CN111225680B (zh) 非酒精性脂肪性肝病的治疗药物
AU2013366690B2 (en) Functionalized exendin-4 derivatives
CN106715466B (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
US10766939B2 (en) Amylin analogues
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
JP7672677B2 (ja) 全用量条件下でｂ型肝炎ウイルス関連肝疾患を治療する医薬品および方法
EP4049673A1 (en) Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
CN110831957B (zh) Apoc-ii模拟肽
KR20140071272A (ko) 항 당뇨병 펩타이드로서의 아포리포프로테인 ａｉｖ
AU2021205912A1 (en) FGF-21 conjugate formulations
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
EP4192495A1 (en) Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2018204918A1 (en) Treatment of hepatic disorders
JP2025525365A (ja) 改良されたｇｌｐ－１受容体アゴニストを含む融合タンパク質およびその使用
TW202440649A (zh) 一種包含glp-1 融合蛋白的藥物製劑及其用途
EP2696886A2 (en) C1q/tnf-related protein 12 and compositions and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221101

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230324

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250516

R150 Certificate of patent or registration of utility model

Ref document number: 7684788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150